Live data · NADAC + Part D CY24 · reviewed daily

Iron Sucrose (Venofer)

Parenteral Iron Replacement class · 3 generic manufacturers · 9 ANDAs filed at FDA.

First FDA approval2000-11-10
Generic availableYes · 3 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
$12.21/unit
3 NDCs benchmarked, lowest of all strengths.
Average NADAC
$12.21
Across all dosage forms in distribution.
Highest NADAC
$12.21
Range is tight.
Plans with PA
0 / 329
Zero PA friction across surveyed plans.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Iron Sucrose used for?

Iron Sucrose is tracked in Medicare Part D. Specific indication information is not available in our current dataset.

Is there a generic for Iron Sucrose?

Yes. 9 ANDAs filed at FDA, 3 generic manufacturers currently shipping.

How much does my plan pay for Iron Sucrose?

Across 329 Part D plans, Iron Sucrose averages $12.21/unit (NADAC). Lowest available: $12.21/unit. Highest in distribution: $12.21/unit.

Is Iron Sucrose on the FDA shortage list?

No. Iron Sucrose is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Sources · every number above traces back.

Last refresh15 Oct 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (3 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.